In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rani Therapeutics LLC

www.ranitherapeutics.com

Latest From Rani Therapeutics LLC

Starts & Stops: First-In-Human Trial Of RaniPill Drug-Delivery Device Begins

Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers Feb. 25 through March 3. Rani Therapeutics announced the first-in-human experience with its novel drug-delivery capsule Feb. 28.

Starts & Stops Tracking Trials

Market Intel: Robotic Pills And The Future Of Painless Drug Delivery

Robotic pill technology, which is already being used for diagnostic purposes, will likely be embraced for the oral delivery of biologic drugs as well. Biologic therapies currently require injections in most cases, but some are exploring specialized robotic pills as a pain-free approach that could increase convenience and compliance, and thus efficacy, of medicines. Several established companies and research centers are working on both diagnostic and biologic therapeutic applications of pill-based technologies.

Gastrointestinal Diagnostics

Shire Snags EU Okay For Von Willebrand Drug Veyvondi

Although noises are still being made in Japan concerning the benefits of Shire's merger with Takeda, the former is going about the business of getting marketing green lights with the latest being for its inherited bleeding disorder treatment Veyvondi in Europe.

Blood & Coagulation Disorders Approvals

Finance Watch: VC Interest Lags At Early Stage – 'Hogwash' Or Evidence-Based?

Venture Capital Edition: A VC investor at a recent conference said it's "hogwash" that venture capitalists aren't interested in funding early-stage biopharma, but the trend toward large financings – such as the $220m raised to date by Rubius – and 2017 investment data suggest otherwise.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Rani Therapeutics LLC
  • Senior Management
  • Mir Imran, Chmn. & CEO
    Svai Sanford, CFO
    Mir Hasham, PhD, VP, R&D
    Stephanie McGrory, VP, Bus. Dev. & Mktg.
    Bob Gaffney, VP, Ops
    Mike Billig, VP, Reg, Quality & Clinical
  • Contact Info
  • Rani Therapeutics LLC
    2051 Ringwood Ave.
    San Jose, CA 95131
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register